profoundmedical.com (PROF) Short-Term Debt to Capital

Profound Medical Corp. (PROF) generates revenue through the supply of advanced TULSA-PRO systems to specialized clinics and urological centers, supplementing sales with consumables. The business relies on the commercialization of robotic MRI technologies for non-invasive prostate cancer therapy. This price chart reflects the impact of drivers such as new insurance codes and equipment implementation, while the individual debt-to-equity ratio stands at 0.09.

The development of the TULSA-PRO system by Profound Medical Corp. (PROF) requires significant investments in commercialization and the production of consumables. This indicator is calculated as the ratio of liabilities with a maturity of up to one year to total equity. An increase in this metric signals rising financial pressure and a higher WACC, which is critical for high-tech companies. The dynamics of the short-term debt-to-equity ratio allow for a real-time assessment of liquidity risk.